IA-05

 

Model: IA-05

Category: Pharmaceutical

Exhibitor: IMMUNADD INC.

Booth No: M629

 

Characteristic

 

IA-05: A Synthetic Next-Generation Adjuvant Accelerating Vaccine and Immunotherapy Development
In an era of rapid advancement in vaccine and immunotherapy technologies, IA-05, a synthetic saponin-based adjuvant under development by ImmunAdd, offers vaccine developers and industry partners a new solution with enhanced stability, purity, and scalability. Whether applied in infectious disease vaccine design, cancer immunotherapy, or as a substitute for natural saponins, IA-05 plays a critical role in supporting the establishment of a high-quality, low-risk supply chain. As a versatile and expandable platform, IA-05 is well-suited for long-term collaborations with vaccine developers, biopharmaceutical companies, CDMOs, and CROs.
[Key Technical Features]
Structure-Driven Optimization: IA-05 is a fully synthetic adjuvant, structurally refined from natural saponins. By eliminating unstable sugar branches while preserving key immunoactive moieties, IA-05 achieves excellent water solubility and flexible formulation compatibility.
High Purity and Batch Consistency: Unlike conventional plant-derived adjuvants, IA-05 offers a single-component, highly purified profile with superior batch-to-batch consistency, facilitating manufacturing quality control and regulatory compliance.
Scalable Synthetic Manufacturing: Produced through small-molecule synthetic pathways, IA-05 supports efficient scale-up, cost management, and cGMP-ready production capabilities.
Broad Application Potential: IA-05 is suitable for use in vaccine adjuvant systems, cancer immunotherapy formulations, dosage form design, adjuvant benchmarking, and differentiated product development.
[Collaboration Models]
Technology Licensing or Co-Development Programs
Preclinical Product Development and Early Comparative Testing

 

Other Products

 

• 

  IAS-01

 

 

 

Back